<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03488108</url>
  </required_header>
  <id_info>
    <org_study_id>16-003335</org_study_id>
    <nct_id>NCT03488108</nct_id>
  </id_info>
  <brief_title>Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women</brief_title>
  <official_title>A Randomized Controlled Trial Comparing Platelet Rich Plasma (PRP) to Minoxidil Foam for Treatment of Androgenic Alopecia in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this proposal is to conduct a study that assesses the safety,
      feasibility and efficacy of using PRP to treat this type of hair loss.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 23, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hair Growth</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean morbidity symptoms</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Level of Pain at PRP Injection Sites</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing Swelling on Scalp</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing Erythema on Scalp</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Experiencing Warmth on Scalp</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Alopecia</condition>
  <arm_group>
    <arm_group_label>Platelet Rich Plasma first, then Minoxidil Foam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized into the Platelet Rich Plasma group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Minoxidil Foam for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minoxidil Foam first, then Platelet Rich Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized into the Minoxidil Foam group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Platelet Rich Plasma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Platelet Rich Plasma</intervention_name>
    <description>Autologous Platelet Rich Plasma (PRP) will be isolated from blood collected from each subject at each treatment time point. 100 cc of PRP will be injected with a 30-gauge needle over the affected part of the scalp, approximately 1/10 cc/injection site. Treatments will take place every 4 weeks for a total of 3 treatments over 12 weeks.</description>
    <arm_group_label>Platelet Rich Plasma first, then Minoxidil Foam</arm_group_label>
    <arm_group_label>Minoxidil Foam first, then Platelet Rich Plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minoxidil Foam</intervention_name>
    <description>Minoxidil 5% topical foam will be applied once daily following manufacturer's instructions for a total of 12 weeks.</description>
    <arm_group_label>Platelet Rich Plasma first, then Minoxidil Foam</arm_group_label>
    <arm_group_label>Minoxidil Foam first, then Platelet Rich Plasma</arm_group_label>
    <other_name>Rogaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Only female patients are eligible

          2. Patients must be 18 years of age or older

          3. Patients must have Androgenic Alopecia Grade I-II by Ludwig Classification

          4. Patients must have been on stable birth control if premenopausal.

          5. Patients are able and willing to provide written informed consent after the nature of
             the study is fully explained

        Exclusion Criteria:

          1. Patients with clinically abnormal hematology, serum chemistry, or screening laboratory
             results as reviewed by the Principal Investigator

          2. Patients who have undergone topical and systemic therapies for hair loss 3 months
             prior to the procedure

          3. Patients who have used any cosmetic product meant to address hair loss 3 months prior
             to enrollment

          4. Patients taking anti-rheumatic disease medication (including methotrexate or other
             anti-metabolites) within the 3 months prior to study entry.

          5. Patients previously having undergone hair transplant surgery prior to study entry

          6. Patients who are pregnant or currently breast-feeding children as Rogaine for Women is
             contra indicated for these women

          7. Patients who have taken spironolactone in the 3 months prior to study participation

          8. Patients with systemic, rheumatic or inflammatory disease or who are immunosuppressed

          9. Patients with ongoing infectious disease, including HIV and hepatitis

         10. Patients with clinically significant cardiovascular, renal, hepatic, endocrine
             disease, cancer, or diabetes

         11. Patients participating in a study of an experimental drug or medical device within 30
             days of study entry

         12. Patients with history of platelet disorders, bone marrow aplasia, sepsis, or cancer in
             the last 5 years.

         13. Patients taking antiaggregating therapy

         14. Patients on anticoagulant therapy

         15. Patients with tendency to keloid formation

         16. Patients with uncompensated diabetes

         17. Patients with active skin disease or skin infection at intended treatment areas
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Bruce, M.B. Ch.B</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2018</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Alison J. Bruce</investigator_full_name>
    <investigator_title>Associate Professor of Dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minoxidil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

